Entero Therapeutics (NASDAQ:ENTO) Stock Price Down 9% – What’s Next?

Entero Therapeutics, Inc. (NASDAQ:ENTO)’s share price was down 9% during trading on Monday. The stock traded as low as $4.70 and last traded at $4.96. 147,060 shares traded hands during mid-day trading, a decline of 95% from the average session volume of 2,798,922 shares. The stock had previously closed at $5.45.

Entero Therapeutics Price Performance

The stock has a fifty day moving average price of $4.05 and a two-hundred day moving average price of $3.55. The company has a market cap of $7.67 million, a P/E ratio of -2.86 and a beta of 1.19.

Entero Therapeutics Company Profile

Entero Therapeutics, Inc is a clinical-stage biotechnology company focused on developing oral therapies for gastrointestinal diseases. The company’s programs are designed to act primarily within the gastrointestinal tract and address conditions for which existing treatment options may be limited.

Entero’s development portfolio includes latiglutenase, an investigational enzyme therapy intended to break down gluten in the digestive system for people with celiac disease. The company has also pursued proprietary formulations of niclosamide, an orally administered compound being studied for potential use in inflammatory bowel diseases, including ulcerative colitis and Crohn’s disease.

The company was formerly known as First Wave BioPharma, Inc and adopted the Entero Therapeutics name as part of its focus on gastrointestinal therapeutics.